Search
Hengrui Medicine: Subsidiary Receives Approval for Clinical Trial of HRS-9821 Inhalation Powder
1 week ago /
Read about 0 minute
Author：小编
Hengrui Medicine's subsidiary, Guangdong Hengrui, has received approval from the National Medical Products Administration (NMPA) for the clinical trial of HRS-9821 inhalation powder. This medication is designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD). As a small molecule inhibitor of PDE3 and PDE4, HRS-9821 effectively combats respiratory inflammation and dilates the bronchus. To date, approximately 38.43 million yuan has been invested in the research and development of this project. In compliance with regulations, the drug must successfully complete clinical trials and secure approval from the NMPA before it can be commercialized and made available to patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
